No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FUSN Fusion Pharmaceuticals
- 21.550
- 0.0000.00%
Close Jun 4 16:00 ET
1.83BMarket Cap-15392P/E (TTM)
0.000High0.000Low0Volume0.000Open21.550Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)85.06MShares21.60052wk High7.58P/B1.33BFloat Cap2.31052wk Low--Dividend TTM61.58MShs Float21.600Historical High--Div YieldTTM0.00%Amplitude1.980Historical Low--Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AstraZeneca Announced Acquisition on March 19
AstraZeneca Announced Acquisition on March 19
AstraZeneca Acquires Fusion Pharmaceuticals in $2.4 Billion Deal
AstraZeneca (AZN.L, AZN.ST) completed the acquisition of Fusion Pharmaceuticals for a maximum transaction value of $2.4 billion, according to a Tuesday release. The clinical-stage biopharmaceutical co
Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete
Fusion Pharmaceuticals (FUSN) said late Tuesday its $2.4 billion acquisition by an AstraZeneca (AZN) subsidiary was completed. The deal "marks a major step forward" in AstraZeneca's ambition to transf
News On Fusion Pharmaceuticals Inc. (FUSN) Now Under AZN.LN
News On Fusion Pharmaceuticals Inc. (FUSN) Now Under AZN.LN
Express News | AstraZeneca Buys Fusion Pharma for $21 per Share in Cash
Express News | Acquisition of Fusion Pharmaceuticals Completed
Comments
$Fusion Pharmaceuticals(FUSN.US$
Acquisition of Fusion Pharmaceuticals Completed
AstraZeneca Buys Fusion Pharma for $21 per Share in Cash
Acquisition of Fusion Pharmaceuticals Completed
AstraZeneca Buys Fusion Pharma for $21 per Share in Cash
1
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
7
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Fusion Pharmaceuticals(FUSN.US$ 🐂 higher lows probably goes 24 slow grind not interested
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg